Human prokinetic drugs promote gastrointestinal motility in zebrafish

• Published in: Neurogastroenterology and motility Vol. 26; no. 4; pp. 589 - 595
• Main Authors: Zhou, J., Guo, S.‐Y., Zhang, Y., Li, C.‐Q.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2014
• Subjects: Animals; Benzamides - pharmacology; Domperidone - pharmacology; Gastrointestinal Agents - pharmacology; gastrointestinal motility; Gastrointestinal Motility - drug effects; Humans; Magnesium Sulfate - pharmacology; Metoclopramide - pharmacology; Morpholines - pharmacology; Nile red; peristalsis; prokinetic drugs; Zebrafish; gastrointestinal motility; peristalsis; Nile red; zebrafish; prokinetic drugs
• ISSN: 1350-1925; 1365-2982
• DOI: 10.1111/nmo.12306

Background Gastrointestinal (GI) motility disorders are highly prevalent in populations worldwide and the development of effective and safe drug treatments for GI motility disorders has proven challenging. In this study, taking advantage of the transparency of larval zebrafish, we developed a novel zebrafish GI motility model for drug screening and efficacy assessment. Methods Zebrafish at 5 days postfertilization were fed 10 μg/L Nile red for 16 h, followed by drug treatment for 6 h. Tested drugs were delivered into the zebrafish by direct soaking. Drug effect on zebrafish GI motility was quantitatively assessed using GI tract fluorescent image‐based morphometric analysis. During all the periods of the experiments, the zebrafish were not fed any food. Key Results All four human prokinetic drugs (domperidone, metoclopramide, mosapride, and magnesium sulfate) increased zebrafish GI motility, whereas two drugs that inhibit human GI movement (atropine and anisodamine) and two negative control drugs (glucose and vitamin C) did not show statistically significant effect on zebrafish GI motility. Conclusions & Inferences These results suggest that larval zebrafish motility model developed here is a useful tool for whole‐animal in vivo GI transit studies and for assessing prokinetic drugs. Gastrointestinal (GI) motility disorders are highly prevalent in populations worldwide and the development of effective and safe drug treatments for GI motility disorders has proven challenging. In this study, taking advantage of the transparency of larval zebrafish, we developed a novel zebrafish GI motility model for drug screening and efficacy assessment.